Company: CRVO
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001437749-25-013543
Chunk: 35

Company: CervoMed Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 35
---
 2025. Dr. De Rosch currently serves as our Senior Vice President, Regulatory and Government Affairs and Program Management, a position he has held since November 2024, and previously served as a consultant to the Company from July 2024 to September 2024. Prior to joining the Company, Dr. De Rosch consulted on drug development and global regulatory strategies since May 2023. Previously, Dr. De Rosch was Chief Operating Officer at Aura Biosciences (“Aura”) from March 2021 to May 2023, overseeing regulatory affairs, chemistry, manufacturing and controls (“CMC”) / technical operations, program and portfolio management, medical device innovation, and information technology. While at Aura, Dr. De Rosch contributed to Aura becoming a public company and growing from approximately 20 employees to approximately 65 employees to support Phase 3 readiness. Prior to joining Aura, Dr. De Rosch was Chief Regulatory Officer at Epizyme, Inc. (“Epizyme”) where he assisted Epizyme in receiving accelerated approval in the U.S. for its first drug, TAZVERIK®, in two oncology indications. Prior to Epizyme, he was Senior Vice President of Regulatory, Quality, and Medical Writing at Nightstar Therapeutics, Inc., a gene therapy company specializing in treatment of inherited retinal disease, which was acquired by Biogen in 2019. Prior organizations also include Akebia Therapeutics, Voisin Consulting Life Sciences, Inspiration Biopharmaceuticals, Vertex Pharmaceuticals, Berlex Laboratories, Diatide, and Mallinckrodt. At Vertex Pharmaceuticals, Dr. De Rosch led the regulatory strategy and marketing approvals in the U.S. and European Union for Kalydeco®, the first drug to treat the underlying cause of cystic fibrosis. Dr. De Rosch has a B.S. in Chemistry/Biochemistry from the University of Wisconsin-Parkside, and an M.S. and Ph.D. in Inorganic Chemistry from the University of California, San Diego. Dr. De Rosch was designated as a Fellow of the Regulatory Affairs Professional Society (FRAPS) in 2017.

<div align='center'>17

EXECUTIVE COMPENSATION</div>

Summary Compensation Table

The table below provides summary compensation information concerning compensation awarded for service during the years ended December 31, 2024, and2023, to the individuals that served as our “NEOs” – all individuals that served as our principal executive officer and our two